Dimitri F Dimitriou MSc

Chief Executive Officer

Dimitri Dimitriou has 20 years’ experience in the pharmaceutical and biotech industry. His past roles include senior director, worldwide business development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He is the founder and chief executive officer of DyoDelta Biosciences, a company specialising in transactions between pharma and biotech companies and was chief executive officer of the London-based drug discovery company, Xcellsyz. He has a degree in biochemistry from Chelsea College (now Kings College, London) and an MSc in pathology and toxicology from the Royal Postgraduate Medical School (now Imperial College Medical School).


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	Dimitri F Dimitriou MSc Chief Executive Officer Dimitri Dimitriou has 20 years’ experience in the pharmaceutical and biotech industry. His past roles include senior director, worldwide business development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He is the founder and chief executive officer of DyoDelta Biosciences, a company specialising in transactions between pharma and biotech companies and was chief executive officer of the London-based drug discovery company, Xcellsyz. He has a degree in biochemistry from Chelsea College (now Kings College, London) and an MSc in pathology and toxicology from the Royal Postgraduate Medical School (now Imperial College Medical School).